Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells 145,954 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 145,954 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $65.58, for a total transaction of $9,571,663.32. Following the sale, the director owned 1,418,453 shares in the company, valued at $93,022,147.74. The trade was a 9.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Liquidia Stock Performance

Shares of NASDAQ LQDA traded down $0.40 during mid-day trading on Friday, hitting $71.23. The company had a trading volume of 1,693,791 shares, compared to its average volume of 1,738,461. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $72.71. The company has a market capitalization of $6.33 billion, a price-to-earnings ratio of 508.82 and a beta of 0.58. The stock’s 50-day moving average price is $49.18 and its 200-day moving average price is $40.67.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, sell-side analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Institutional Trading of Liquidia

Hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. purchased a new stake in Liquidia in the fourth quarter worth approximately $25,000. NewEdge Advisors LLC bought a new position in Liquidia during the second quarter valued at approximately $25,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia during the third quarter worth approximately $30,000. FNY Investment Advisers LLC bought a new stake in shares of Liquidia in the 3rd quarter worth approximately $34,000. Finally, Covestor Ltd boosted its stake in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Needham & Company LLC boosted their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Lifesci Capital raised Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research report on Monday, May 11th. Finally, Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $60.29.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).